Innovative Cell Therapy Platform Immusoft leverages its proprietary Immune System Programming technology to reprogram patient-derived B cells for sustained protein delivery, offering a unique therapeutic approach that can attract partnerships with biotech and pharmaceutical firms interested in advanced gene therapies.

Recent Clinical Advancement The company's presentation at ASGCT 2025 highlights positive results from its engineered B cell therapies in human trials, presenting opportunities for collaborations with clinical research organizations and investors seeking innovative treatments for rare diseases.

Focus on Rare Diseases Immusoft's specialization in developing therapies for rare and genetic disorders creates potential sales avenues with specialized healthcare providers, patient advocacy groups, and organizations funding orphan drug development.

Funding and Growth Potential With a current funding of $25 million and ongoing NIH grants, Immusoft is positioned for further R&D investments, making it an attractive partner for technology providers and service companies supporting biotech innovation cycles.

Partnerships and Collaborations Strategic alliances, such as the partnership with Takeda to develop B cell therapies crossing the blood-brain barrier, open doors for co-development opportunities and cross-selling of complementing biotech solutions.